AbbVie says atogepant reduced migraine days in Phase III trial
AbbVie is developing atogepant to specifically treat migraine. Credit: AbbVie Inc.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
